Investor Relations



We are a leading science and technology company that delivers life-transforming medicines for serious diseases.

Founded by physician-scientists more than 30 years ago, our science-driven approach has resulted in seven FDA-approved medicines and numerous product candidates in a range of diseases, including cancer, asthma, pain and infectious diseases.

In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human sequencing efforts in the world and rapid response technologies being used for global good.




  • Apr 08

    Regeneron to Report First Quarter 2019 Financial and Operating Results and Host Conference Call and Webcast on May 7, 2019
  • Apr 08

    Regeneron and Alnylam Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases


  • 2019 Annual Meeting of Shareholders
    Jun 14
    10:30 AM EDT
    Jun 14, 2019 | 10:30 AM EDT

  • Regeneron Pharmaceuticals Q1 2019 Earnings Conference Call
    May 7
    8:30 AM EDT
    May 7, 2019 | 8:30 AM EDT